<SEC-DOCUMENT>0001213900-25-016658.txt : 20250224
<SEC-HEADER>0001213900-25-016658.hdr.sgml : 20250224
<ACCEPTANCE-DATETIME>20250224172402
ACCESSION NUMBER:		0001213900-25-016658
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250224
DATE AS OF CHANGE:		20250224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BiomX Inc.
		CENTRAL INDEX KEY:			0001739174
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				823364020
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-275935
		FILM NUMBER:		25658275

	BUSINESS ADDRESS:	
		STREET 1:		22 EINSTEIN ST.
		STREET 2:		FLOOR 4
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			7414003
		BUSINESS PHONE:		972 723942377

	MAIL ADDRESS:	
		STREET 1:		22 EINSTEIN ST.
		STREET 2:		FLOOR 4
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			7414003

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Chardan Healthcare Acquisition Corp.
		DATE OF NAME CHANGE:	20180430
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>ea0231950-424b5_biomx.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: right"><B>Filed pursuant to Rule 424(b)(5)<BR>
Registration No. 333-275935</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt"><B>Prospectus Supplement<BR>
(To the Prospectus dated January 2, 2024)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_001.jpg" ALT="A blue and white logo&#10;&#10;Description automatically generated" STYLE="height: 60px; width: 215px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We previously entered into an
At the Market Offering Agreement, or the offering agreement, with H.C. Wainwright &amp; Co., LLC, or Wainwright, dated December 7, 2023,
relating to the sale of shares of our common stock, par value $0.0001 per share, or our Common Stock, offered by the Prospectus (as defined
below). In accordance with the terms of the offering agreement, we may offer and sell shares of our Common Stock having an aggregate offering
price of up to $7,500,000 million from time to time through Wainwright acting as sales agent, at our discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of February 24, 2025, we have
sold $20,374 of our shares of Common Stock under the offering agreement pursuant to our prospectus dated January 2, 2024, or the Prospectus.
This prospectus supplement should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent
that the information herein amends or supersedes the information contained in the Prospectus. This prospectus supplement is not complete
without, and may only be delivered or utilized in connection with, the Prospectus, and any future amendments or supplements thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The purpose of this prospectus
supplement is to suspend the offering agreement and to terminate the continuous offering by us under the Prospectus effective on February
24, 2025. We will not make any sales of our shares of Common Stock pursuant to the offering agreement unless and until a new prospectus
supplement is filed with the Securities and Exchange Commission; however, the offering agreement remains in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our common stock is listed on
the NYSE American under the symbol &ldquo;PHGE.&rdquo; On February 21, 2025, the last reported sale price of our Common Stock on the NYSE
American was $0.9588 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Investing
in our securities involves a high degree of risk. See&nbsp;</B>&ldquo;<B>Risk Factors</B>&rdquo;<B>&nbsp;beginning on page 7 of the Prospectus,
the&nbsp;</B>&ldquo;<B>Risk Factors</B>&rdquo;<B>&nbsp;section beginning on page 28 of our Annual Report on Form 10-K for the year ended
December 31, 2023, and under similar headings in the other documents that are filed after the date hereof and incorporated by reference
into this prospectus supplement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or
accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>February 24, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ -<# 2(  A$! Q$!_\0
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M/L3R'R1HOA37O$$RQZ9I=Q*"<&0H50?5CQ7M^G^!(O!/PVUU9)1-?W%F[3S
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M*HP*J6(;V)Y#C-%\(6?@OP)?V$)\R=[>1YYR,&1MI_0=A7RP'%?;CJK(0P#
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:?QHK6AMX8<F*)$SUVJ!FBL6>K3C)12;/_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
